ES2193152T3 - Nueva proteina de la orina denominada componente b. - Google Patents

Nueva proteina de la orina denominada componente b.

Info

Publication number
ES2193152T3
ES2193152T3 ES94904167T ES94904167T ES2193152T3 ES 2193152 T3 ES2193152 T3 ES 2193152T3 ES 94904167 T ES94904167 T ES 94904167T ES 94904167 T ES94904167 T ES 94904167T ES 2193152 T3 ES2193152 T3 ES 2193152T3
Authority
ES
Spain
Prior art keywords
urine
new protein
designated component
protein
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94904167T
Other languages
English (en)
Inventor
Antonino Sirna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2193152T3 publication Critical patent/ES2193152T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBE UNA NUEVA PROTEINA QUE SE OBTIENE A PARTIR DE URINA A TRAVES DE UN PROCESO DE EXTRACCION Y PURIFICACION MEDIANTE CROMATOGRAFIA DE INTERCAMBIOS DE IONES Y CROMATOGRAFIA DE ALTA RESOLUCION, CON UN PESO MOLECULAR DE ALREDEDOR DE GKDA Y QUE TIENE PROPIEDADES ANTIINFLAMATORIAS, ANTICOAGULANTES Y ANTITUMORALES. LA PROTEINA INHIBE LA UNION DEL TGF-ALFA A SU RECEPTOR.
ES94904167T 1992-12-22 1993-12-21 Nueva proteina de la orina denominada componente b. Expired - Lifetime ES2193152T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920919A IT1257184B (it) 1992-12-22 1992-12-22 Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale

Publications (1)

Publication Number Publication Date
ES2193152T3 true ES2193152T3 (es) 2003-11-01

Family

ID=11401349

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94904167T Expired - Lifetime ES2193152T3 (es) 1992-12-22 1993-12-21 Nueva proteina de la orina denominada componente b.

Country Status (19)

Country Link
US (1) US5908827A (es)
EP (1) EP0675956B1 (es)
JP (1) JP3025014B2 (es)
KR (1) KR100193107B1 (es)
AT (1) ATE236976T1 (es)
AU (1) AU690093B2 (es)
CA (1) CA2151156A1 (es)
DE (1) DE69332861T2 (es)
DK (1) DK0675956T3 (es)
ES (1) ES2193152T3 (es)
FI (2) FI114478B (es)
IL (1) IL108149A (es)
IT (1) IT1257184B (es)
NO (1) NO315800B1 (es)
PT (1) PT675956E (es)
RU (1) RU2177480C2 (es)
UA (1) UA46702C2 (es)
WO (1) WO1994014959A1 (es)
ZA (1) ZA939621B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234110T1 (de) * 1996-04-24 2003-03-15 Applied Research Systems Komponente b als wundheilendes mittel
AU8536698A (en) * 1997-06-09 1998-12-30 Wolf-Georg Forssmann Lus-1 human protein, its production and use
DK1093380T3 (da) * 1998-07-09 2003-01-27 Applied Research Systems Komponent B som angiogent middel i kombination med humane vækstfaktorer
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
ES2359408T3 (es) * 2003-04-16 2011-05-23 Merck Serono Sa Uso de slurp-1 para tratar enfermedades relacionadas con la disfunción de receptores de acetilcolina.
US7343581B2 (en) * 2005-06-27 2008-03-11 Tela Innovations, Inc. Methods for creating primitive constructed standard cells
US7590968B1 (en) 2006-03-01 2009-09-15 Tela Innovations, Inc. Methods for risk-informed chip layout generation
US8653857B2 (en) 2006-03-09 2014-02-18 Tela Innovations, Inc. Circuitry and layouts for XOR and XNOR logic
US9563733B2 (en) 2009-05-06 2017-02-07 Tela Innovations, Inc. Cell circuit and layout with linear finfet structures
US8448102B2 (en) 2006-03-09 2013-05-21 Tela Innovations, Inc. Optimizing layout of irregular structures in regular layout context
US8225239B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining and utilizing sub-resolution features in linear topology
US9009641B2 (en) 2006-03-09 2015-04-14 Tela Innovations, Inc. Circuits with linear finfet structures
US9230910B2 (en) 2006-03-09 2016-01-05 Tela Innovations, Inc. Oversized contacts and vias in layout defined by linearly constrained topology
US7763534B2 (en) 2007-10-26 2010-07-27 Tela Innovations, Inc. Methods, structures and designs for self-aligning local interconnects used in integrated circuits
US8245180B2 (en) 2006-03-09 2012-08-14 Tela Innovations, Inc. Methods for defining and using co-optimized nanopatterns for integrated circuit design and apparatus implementing same
US9035359B2 (en) 2006-03-09 2015-05-19 Tela Innovations, Inc. Semiconductor chip including region including linear-shaped conductive structures forming gate electrodes and having electrical connection areas arranged relative to inner region between transistors of different types and associated methods
US8541879B2 (en) 2007-12-13 2013-09-24 Tela Innovations, Inc. Super-self-aligned contacts and method for making the same
US8247846B2 (en) 2006-03-09 2012-08-21 Tela Innovations, Inc. Oversized contacts and vias in semiconductor chip defined by linearly constrained topology
US7943967B2 (en) 2006-03-09 2011-05-17 Tela Innovations, Inc. Semiconductor device and associated layouts including diffusion contact placement restriction based on relation to linear conductive segments
US8225261B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining contact grid in dynamic array architecture
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
US7917879B2 (en) * 2007-08-02 2011-03-29 Tela Innovations, Inc. Semiconductor device with dynamic array section
US7956421B2 (en) 2008-03-13 2011-06-07 Tela Innovations, Inc. Cross-coupled transistor layouts in restricted gate level layout architecture
US8658542B2 (en) 2006-03-09 2014-02-25 Tela Innovations, Inc. Coarse grid design methods and structures
US8839175B2 (en) 2006-03-09 2014-09-16 Tela Innovations, Inc. Scalable meta-data objects
US7932545B2 (en) 2006-03-09 2011-04-26 Tela Innovations, Inc. Semiconductor device and associated layouts including gate electrode level region having arrangement of six linear conductive segments with side-to-side spacing less than 360 nanometers
US7586800B1 (en) 2006-08-08 2009-09-08 Tela Innovations, Inc. Memory timing apparatus and associated methods
US7979829B2 (en) * 2007-02-20 2011-07-12 Tela Innovations, Inc. Integrated circuit cell library with cell-level process compensation technique (PCT) application and associated methods
US8286107B2 (en) 2007-02-20 2012-10-09 Tela Innovations, Inc. Methods and systems for process compensation technique acceleration
US8667443B2 (en) 2007-03-05 2014-03-04 Tela Innovations, Inc. Integrated circuit cell library for multiple patterning
EP2201035B1 (en) * 2007-09-20 2015-06-17 Commonwealth Scientific and Industrial Research Organisation Novel avian cytokines and genetic sequences encoding same
WO2009051109A1 (ja) * 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
US8453094B2 (en) 2008-01-31 2013-05-28 Tela Innovations, Inc. Enforcement of semiconductor structure regularity for localized transistors and interconnect
US7939443B2 (en) 2008-03-27 2011-05-10 Tela Innovations, Inc. Methods for multi-wire routing and apparatus implementing same
KR101903975B1 (ko) 2008-07-16 2018-10-04 텔라 이노베이션스, 인코포레이티드 동적 어레이 아키텍쳐에서의 셀 페이징과 배치를 위한 방법 및 그 구현
US9122832B2 (en) 2008-08-01 2015-09-01 Tela Innovations, Inc. Methods for controlling microloading variation in semiconductor wafer layout and fabrication
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2239322A1 (en) * 2009-04-07 2010-10-13 Basf Se Use of enzymes to reduce formaldehyde from formaldehyde-containing products
US8661392B2 (en) 2009-10-13 2014-02-25 Tela Innovations, Inc. Methods for cell boundary encroachment and layouts implementing the Same
US9159627B2 (en) 2010-11-12 2015-10-13 Tela Innovations, Inc. Methods for linewidth modification and apparatus implementing the same
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
SU1751206A1 (ru) * 1990-06-04 1992-07-30 Всесоюзный научно-исследовательский противочумный институт "Микроб" Рекомбинантна плазмидна ДНК РЕК 8, кодирующа фибринолизин YeRSINIa реSтIS, способ ее конструировани и штамм бактерий ЕSснеRIснIа coLI - продуцент фибринолизина YeRSINIa реSтIS
US5298604A (en) * 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes

Also Published As

Publication number Publication date
IT1257184B (it) 1996-01-10
RU2177480C2 (ru) 2001-12-27
AU5833594A (en) 1994-07-19
FI116059B (fi) 2005-09-15
ITRM920919A1 (it) 1994-06-22
JPH08509359A (ja) 1996-10-08
DK0675956T3 (da) 2003-07-07
ATE236976T1 (de) 2003-04-15
KR950704486A (ko) 1995-11-20
NO952494D0 (no) 1995-06-21
IL108149A0 (en) 1994-04-12
IL108149A (en) 2005-05-17
NO315800B1 (no) 2003-10-27
DE69332861D1 (de) 2003-05-15
UA46702C2 (uk) 2002-06-17
WO1994014959A1 (en) 1994-07-07
ZA939621B (en) 1995-06-22
PT675956E (pt) 2003-07-31
FI953091L (fi) 1995-06-21
FI20040608A7 (fi) 2004-04-29
EP0675956A1 (en) 1995-10-11
KR100193107B1 (ko) 1999-06-15
JP3025014B2 (ja) 2000-03-27
FI114478B (fi) 2004-10-29
DE69332861T2 (de) 2004-01-29
AU690093B2 (en) 1998-04-23
CA2151156A1 (en) 1994-07-07
US5908827A (en) 1999-06-01
NO952494L (no) 1995-08-21
FI953091A0 (fi) 1995-06-21
ITRM920919A0 (it) 1992-12-22
EP0675956B1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
EA199800733A1 (ru) Антагонисты рецептора il-8
EA199700265A1 (ru) Добавочный протеин рецептора интерлейкина-1 человека
FI953091A0 (fi) Virtsasta peräisin oleva uusi proteiini, jota kutsutaan komponentti B:ksi
ES2135866T3 (es) Procedimiento de hidroformilacion.
MX9203660A (es) Receptores del factor alta y -beta de la necrosis del tumor.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
EA199700421A1 (ru) Искуственная разделительная мембрана
ES2135597T3 (es) Inmunoensayos fluorescentes de canalizacion del oxigeno.
MX9203820A (es) Ultrapurificacion del factor viii utilizando anticuerpos monoclonales.
BR9815314A (pt) Transdutor para transformação de séries de dados sintáticos
IT1205953B (it) Procedimento per la disidratazione di fanghi da acque di scarico,con particolare riferimento a filtropresse
ES2122905A1 (es) Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
EA200000536A1 (ru) Применение комбинации ингибитора конвертирующего фермента и диуретика для лечения нарушений микроциркуляции
MX9101369A (es) Procedimiento de alto catalizador para la produccion de detergentes de glucamida,con catalizador de alta concentracion
DE59003512D1 (de) Hochdruckentladungslampe.
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
DK0734392T3 (da) Omdannelse af bisnoralkohol til bisnoraldehyd
FR2646696B1 (fr) Ensemble de raccordement, notamment pour raccord rapide de canalisation
DE59007201D1 (de) Hochdruckentladungslampe.
ATA224588A (de) Kesselfahrzeug, insbesondere schlammsaugfahrzeug
ES2147365T3 (es) Un procedimiento para la preparacion del factor ix a partir de muestras biologicas.
AT386670B (de) Leuchte, insbesondere strassenleuchte
KR910009271A (ko) 15-케토-프로스타글란딘 화합물을 이용한 폐 부전증의 치료
DE69001971D1 (de) Einlassleitung.
FI892042L (fi) Tryckledning.